Abstract:Background The Regulatory T cell (Treg) lineage is defined by the transcription factor FOXP3, which controls immune-suppressive gene expression profiles. Tregs are often recruited in high frequencies to the tumor microenvironment where they can suppress antitumor immunity. We hypothesized that pharmacological inhibition of FOXP3 by systemically delivered, unformulated constrained ethyl-modified antisense oligonucleotides could modulate the activity of Tregs and augment antitumor immunity providing therapeutic benefit in cancer models and potentially in man. Methods We have identified murine Foxp3 antisense oligonucleotides (ASOs) and clinical candidate human FOXP3 ASO AZD8701. Pharmacology and biological effects of FOXP3 inhibitors on Treg function and antitumor immunity were tested in cultured Tregs and mouse syngeneic tumor models. Experiments were controlled by vehicle and non-targeting control ASO groups as well as by use of multiple independent FOXP3 ASOs. Statistical significance of biological effects was evaluated by one or two-way analysis of variance with multiple comparisons. Results AZD8701 demonstrated a dose-dependent knockdown of FOXP3 in primary Tregs, reduction of suppressive function and efficient target downregulation in humanized mice at clinically relevant doses. Surrogate murine FOXP3 ASO, which efficiently downregulated Foxp3 messenger RNA and protein levels in primary Tregs, reduced Treg suppressive function in immune suppression assays in vitro. FOXP3 ASO promoted more than 70% reduction in FOXP3 levels in Tregs in vitro and in vivo, strongly modulated Treg effector molecules (eg, ICOS, CTLA-4, CD25 and 4-1BB), and augmented CD8 + T cell activation and produced antitumor activity in syngeneic tumor models. The combination of FOXP3 ASOs with immune checkpoint blockade further enhanced antitumor efficacy. Conclusions Antisense inhibitors of FOXP3 offer a promising novel cancer immunotherapy approach. AZD8701 is being developed clinically as a first-in-class FOXP3 inhibitor for the treatment of cancer currently in Ph1a/b clinical trial ( NCT04504669 ).

Tolerogenic DNA Vaccine for Prevention of Autoimmune Ovarian Disease

Treatment of Autoimmune Ovarian Disease by Co‐administration with Mouse Zona Pellucida Protein 3 and DNA Vaccine Through Induction of Adaptive Regulatory T Cells

FK506 As an Adjuvant of Tolerogenic DNA Vaccination for the Prevention of Experimental Autoimmune Encephalomyelitis.

Enhanced Contraceptive Response by Co‐immunization of DNA and Protein Vaccines Encoding the Mouse Zona Pellucida 3 with Minimal Oophoritis in Mouse Ovary

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Intramuscular Injection of Interleukin-10 Plasmid DNA Prevented Autoimmune Diabetes in Mice

Treg Cell Resistance to Apoptosis in DNA Vaccination for Experimental Autoimmune Encephalomyelitis Treatment.

Protective Response Against Type 1 Diabetes in Nonobese Diabetic Mice after Coimmunization with Insulin and Dna Encoding Proinsulin

Protein/DNA vaccine-induced antigen-specific Treg confer protection against asthma.

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

Induction of Immune Tolerance in Asthmatic Mice by Vaccination with DNA Encoding an Allergen-Cytotoxic T Lymphocyte-Associated Antigen 4 Combination.

Induction of Active Immune Suppression by Co-Immunization with DNA- and Protein-Based Vaccines.

Potential Therapy of Fc-Antigen Combination-Encoding Dna Vaccination in Mouse Allergic Airway Inflammation

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Cutting Edge: Immunosuppressant As Adjuvant for Tolerogenic Immunization.

Co-inoculation of DNA and protein vaccines induces antigen-specific T cell suppression.

Vaccination with Ia-2 Autoantigen Can Prevent Late Prediabetic Nonobese Diabetic Mice from Developing Diabetes Mellitus

Enhancedanti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody

Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand.

Intranasal co-administration with the mouse zona pellucida 3 expressing construct and its coding protein induces contraception in mice.

Anti-idiotypic Regulatory Responses Induced by Vaccination with DNA Encoding Murine TCR Valpha5 and Vbeta2.